Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy

MLA

Maria Fleseriu, et al. “Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy.” Journal of the Endocrine Society, vol. 5, May 2021, pp. A518–19. EBSCOhost, https://doi.org/10.1210/jendso/bvab048.1058.

APA

Maria Fleseriu, Andrey Verbovoy, Murray B. Gordon, Mark E. Molitch, Yulia Pokramovich, Nienke Biermasz, Alexander Dreval, Nina Leonova, Christian J. Strasburger, Sergey A. Dogadin, William H. Ludlam, Irina Bondar, Elena Isaeva, Gerald Raverot, Gilgun-Sherki Yossi, Djuro P Macut, Gary Patou, Asi Haviv, & Shlomo Melmed. (2021). Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. Journal of the Endocrine Society, 5, A518–A519. https://doi.org/10.1210/jendso/bvab048.1058

Chicago

Maria Fleseriu, Andrey Verbovoy, Murray B. Gordon, Mark E. Molitch, Yulia Pokramovich, Nienke Biermasz, Alexander Dreval, et al. 2021. “Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy.” Journal of the Endocrine Society 5 (May): A518–19. doi:10.1210/jendso/bvab048.1058.